Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Atai Beckley Inc.NASDAQ: ATAI

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow dips below year-ago levels

Q2 FY2026 financing cash flow of $2.64M fell 66.0% year over year, behind the +187.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 221.1% from the prior quarter. Over 3 fiscal years it compounded at +134.9% a year.

Context

  • Financing cash flow amounted to 6590.4% of revenue in FY2025, up 4845.6 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -66.0% toward the trailing-twelve-month pace of +187.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.64M+221.1% QoQ
Last fiscal yearDec 2025
$269.48M+4914.5% YoY
LTMJun 2026
$208.16M+187.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.0%——
1 year+4914.5%——
3-year CAGR+134.9%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
269.48M USD
Year-over-year change
+4914.5%
4-year CAGR
-10.0%

Financing Cash Flow vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +187.5% is the 5th highest of 11, against a peer median of +112.9%.
  • Financing cash flow amounts to 4653.7% of revenue for ATAI, versus a peer median of 3223.1%.
ATAI Competitors
Financing Cash Flow for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NKTRNektar TherapeuticsLTM Jun 2026$1.07B USD+342086.6%+392.9%1968.3%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$1.03B USD+2428.7%+42.6%54053.9%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$554.65M USD+115.5%-15.9%—
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$476.48M USD+84.5%——
RLAYRelay Therapeutics, Inc.LTM Jun 2026$463.47M USD+110.3%-82.3%4478.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$306.39M USD+17210.3%+114.1%—
ATAIAtai Beckley Inc.LTM Jun 2026$208.16M USD+187.5%+134.9%4653.7%
SANASana Biotechnology, Inc.LTM Mar 2026$127.62M USD+790.4%+197.0%—
IMTXImmatics N.V.LTM Mar 2026€118.48M EUR-17.9%-8.9%317.7%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$77.07M USD-42.0%-26.8%5928.4%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$20.66M USD-94.1%-57.0%9.5%
Peer median (excluding ATAI) —+112.9%-8.9%3223.1%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.24M)(157.42M)(43.9M)(150.05M)(660.05M)
Depreciation & Amortization47K168K319K473K1.01M
Deferred Income Tax39.14M5.07M000
Stock-Based Compensation63.36M42.38M32.98M25.49M0
Change in Working Capital(7.6M)(3.34M)7.47M(9.2M)(6.48M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.3M(3.03M)2.14M(1.87M)(1.7M)
Other Working Capital(9.9M)(301K)5.33M(7.33M)(4.78M)
Other Non-Cash Items16.06M8.67M(80.99M)50.85M562.84M
Operating Cash Flow(63.25M)(104.47M)(84.12M)(82.44M)(102.68M)
Capital Expenditures(1.13M)(1.02M)(590K)(95K)(901K)
Acquisitions (Net)(52.94M)0(443K)359K4.64M
Purchases of Investments(23.66M)(309.66M)(186.22M)(15M)(98.95M)
Sales of Investments(955K)226.83M139.47M82.01M9.05M
Other Investing Activities(2.6M)(3.25M)(5.84M)(8.1M)(13M)
Investing Cash Flow(81.28M)(86.85M)(53.3M)59.17M(109.13M)
Debt Repayment1.59M15M05M7.71M
Common Stock Issued409.88M00535K283.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.42M5.19M(8.36M)(161K)(21.66M)
Financing Cash Flow409.86M20.79M(8.36M)5.37M269.48M
Effect of Forex Changes(320K)(1.12M)189K362K116K
Net Change in Cash265.02M(171.65M)(145.58M)(17.53M)57.8M
Free Cash Flow(64.37M)(105.49M)(84.71M)(82.53M)(103.58M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.